The Chief Executive Officer (CEO)
South African National Blood Services (SANBS)
1 Constantia Blvd, Roodepoort,
South Africa, 1715

The Chief Executive Officer (CEO)
Western Cape Blood Service (WCBS)
Old Mill Road, Pinelands,
Cape Town, 7450

Att: *Mr Ravi Reddy (SANBS)*
Dr Gregory Bellairs (WCBS)

CC: *To Whom It May Concern*

Ref to *P L NUTT*

DOCref: SANBS_WCBS~Let~22n001vA1

31 October 2022 **Draft**

Re: Investigating the safety and consequences of blood transfusion from SARS-COVID-19 vaccine-trial donors

Dear Mr Reddy and Dr Bellairs,

From 2020 there have been peer reviewed reports of blood disorders in COVID-19 vaccine recipients. An example of this is a syndrome now termed Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). A current Pubmed (nih.gov) search of VITT delivers 442 related articles from 2021-2022. Laboratory testing has been documented for suspected cases.[1]

Studies have also shown that delivered messenger ribonucleic acid (mRNA) can trigger the production of distinct antigens that distribute systemically.[2,3,4,5] This is radically different from conventional platforms (i.e. inactivated whole-virus vaccines or even protein-subunit nanoparticle vaccines), where the produced antigen and its distribution are more predictable.[6]

The synthetic pseudouridine-containing mRNA technology used in these COVID-19 'vaccines' is a concern.[7] The National Health Act, 61 of 2003 "prohibits the manipulation of genetic material from either adult, zygotic or embryonic cells in order to alter, for therapeutic purposes, the function of cells or tissues". This raises problematic questions in light of liver cell line studies demonstrating that BNT162b2 mRNA is reverse transcribed intracellularly into DNA upon BNT162b2 exposure.[4,8]

If we further explore the nature of the COVID-19 gene-based 'vaccines' and the regulatory status of these interventions, they remain under clinical trial governance. To our knowledge, the SANBS and WCBS have not fully established the safety of vaccine-containing transfusion-transmitted blood products or by-products, or amended the informed consent process that they are following with blood and blood product recipients. Satisfactory informed consent is full disclosure of the possible content of blood and the

PO Box 1158, Houghton, Johannesburg, South Africa Telephone : +27 11 648 5101 Email : office@emlct.com

potential of adverse events, and there is a clear concern from current peer reviewed reports, as well as VAERS and SAVAERS published data, which reveal the presence of risk of serious adverse events.[5,6,9,10]

Furthermore, according to the World Health Organization (WHO), "*An important component of a blood safety system is the establishment of haemovigilance, which includes efforts to monitor and evaluate adverse events associated with the blood supply and transfusion service and to use the findings to improve blood safety and transfusion outcomes.*"[11] To date, there is no statement from the SANBS or WCBS as to the analysis and safety precautions taken for the blood received from SARS-COVID-19 vaccine trial donors or regarding the process of informed consent regarding the donor vaccine trial status.[12,13,14]

The South African "Vaccine" Injury Medico-Legal Study-Group (SAVIMS) hereby request an immediate response to the following:

1. With no formal completion and outcome on any of the COVID-19 vaccine clinical trials, what are the SANBS and WCBS directives and accountability to ensure safety of the recipients of blood and blood products?
2. Currently the Health Questionnaire limits the vaccine trial status to the "past 3 months." On what evidence-based literature data has the SANBS and WCBS resolved this time value to a clinical trial product?
3. There is an urgency for transparency and minimising of individual human rights violation. On what evidence-based data has the information of donors' clinical trial status been omitted from the blood recipient?

Trusting this matter, of patent national interest as shown above, to be resolved with due promptness by your respective offices.

Yours faithfully,

ADMIN OFFICER - SAVIMS
Peter L NUTT, Pr Eng +264 81 124 1609
Pete.PNA01@gmail.com

References

[1] Favaloro EJ. Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia. Int J Lab Hematol. 2021 Aug;43(4):559-570. doi: 10.1111/ijlh.13629. Epub 2021 Jun 17.
[2] Heinz F.X., Stiasny K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines. 2021;6:104.
[3] Watad et al. Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination. Vaccines (Basel). 2021 Apr 29;9(5):435. doi: 10.3390/vaccines9050435. PMID: 33946748; PMCID: PMC8146571.
[4] Aldén et al. Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line; Curr. Issues Mol. Biol. 2022, 44(3), 1115-1126; https://doi.org/10.3390/cimb44030073
[5] Fraiman et al. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults; https://doi.org/10.1016/j.vaccine.2022.08.036; 0264-410X/Ó 2022. Published by Elsevier Ltd.
[6] Trougakos et al. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends Mol Med. 2022 Jul;28(7):542-554. doi: 10.1016/j.molmed.2022.04.007. Epub 2022 Apr 21. PMID: 35537987; PMCID: PMC9021367.

[7] Cumulative Analysis of Post-authorization Adverse Event Reports. https://www.researchgate.net/publication/358266490_FOIA_Release_-_536_Cumulative_Analysis_of_Post-authorization_Adverse_Event_Reports_EXPLOSIVE_List_of_100s_of_known_adverse_events_for_the_Pfizer_CoV-2_Injections
[8] No. 61 of 2003: National Health Act, 2004 (South Africa)
[9] Cumulative Analysis of Post-authorization Adverse Event Reports. https://www.researchgate.net/publication/358266490_FOIA_Release_-_536_Cumulative_Analysis_of_Post-authorization_Adverse_Event_Reports_EXPLOSIVE_List_of_100s_of_known_adverse_events_for_the_Pfizer_CoV-2_Injections
[10] Informed Consent for Covid-19 "Vaccination"; Ref Nr: '22n001_vA1 Date: 24 Aug '22 9; EMLCT SAVIMS-C-19-Jabs-Informed-Consent-1.pdf
[11] Global status report on blood safety and availability 2021. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. (9789241565431-eng.pdf)
[12] Collection of blood from vaccinated donors; https://sanbs.org.za/media-release/collection-of-blood-from-vaccinated-donors
[13] COVID-19 FAQ's; https://sanbs.org.za/wp-content/uploads/2020/04/SANBS-COVID-19-FAQs.pdf
[14] Informed Consent; WCBS; www.wcbs.org.za/clinical-information/haemovigilance-reports/